<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Screening for cervical cancer in patients with HIV infection and other immunocompromised states
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Screening for cervical cancer in patients with HIV infection and other immunocompromised states
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Screening for cervical cancer in patients with HIV infection and other immunocompromised states
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William R Robinson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3877873757">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Screening for cervical cancer is of particular importance for patients with HIV infection or in other immunocompromised states. Studies suggest that the incidence of cervical intraepithelial neoplasia (CIN), as confirmed by colposcopy, is four to five times higher in patients with HIV compared with patients without HIV but with high-risk sexual behaviors [
         <a href="#rid1">
          1-3
         </a>
         ]. CIN is common in patients with HIV because [
         <a href="#rid4">
          4-8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human papillomavirus (HPV) infection, the leading pathogen of most cervical cancers, is endemic among sexually active individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with HIV are more likely to have persistent HPV infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent infection with one or more oncogenic HPV subtypes is a major factor in the pathogenesis of premalignant and malignant cervical disease.
        </p>
        <p>
        </p>
        <p>
         Despite advances in management of patients with HIV and increases in HPV vaccination, screening for cervical cancer continues to require attention. One study reported that as many as one-fourth of patients with HIV do not get an annual Pap test despite seeing a primary care clinician during that time period, underscoring the need for continued emphasis on cervical cancer screening in this population [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Specific issues regarding screening for cervical cancer and evaluation of abnormal screening results in patients with HIV or other immunocompromised states will be reviewed here.
        </p>
        <p>
         Management of CIN in patients with HIV and general issues regarding screening for cervical cancer in patients without HIV are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3245.html" rel="external">
          "Preinvasive and invasive cervical neoplasia in patients with HIV infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">
          "Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1166593988">
         <span class="h1">
          OUR APPROACH TO SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple expert groups have devised consensus guidelines for cervical cancer screening in patients with HIV [
         <a href="#rid10">
          10-15
         </a>
         ]. Our approach to screening for cervical cancer in patients with HIV is consistent with those published by the United States Department of Health and Human Services along with the National Institutes of Health [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1848131991">
         <span class="h2">
          Initial screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the initial screening visit for cervical cancer screening in patients with HIV is as follows [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cervical cancer screening is initiated at the time of HIV diagnosis, but no sooner than 21 years of age. This is similar to patients without HIV, in whom cervical cancer screening is also initiated at the age of 21 years. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Screening in average-risk patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While historically earlier screening (ie, prior to age 21 years) was performed, the risk of developing cervical cancer prior to the age of 21 years is rare. In a report from the 2002 to 2016 HIV/AIDS Cancer Match Study including over 160,000 females with HIV, of the 552 patients who developed invasive cervical cancer, no cases occurred in patients &lt;25 years of age [
         <a href="#rid16">
          16
         </a>
         ]. Thus, screening beginning at age 21 years provides a several-year window prior to age 25 years, when the risk of cervical cancer begins to increase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients 21 to 29 years, cervical cytology is used for screening. For patients ≥30 years, either cervical cytology or co-testing (cervical cytology and human papillomavirus [HPV] testing) is acceptable for screening. Primary HPV testing (HPV testing without cervical cytology) is
         <strong>
          not
         </strong>
         approved for use in patients with HIV. (See
         <a class="local">
          'Cytology'
         </a>
         below and
         <a class="local">
          'Cotesting'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform a screening colposcopy at this visit. This is discussed in more detail below. (See
         <a class="local">
          'Routine colposcopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Given the high rate of multifocal HPV disease and HPV-associated neoplasms, the examination also includes a thorough visual inspection of the anus, vulva, and vagina [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2678681070">
         <span class="h2">
          Subsequent screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to subsequent cervical cancer screening for patients with HIV in whom initial screening is
         <strong>
          normal
         </strong>
         is as follows [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If screening with
         <strong>
          cervical cytology
         </strong>
         (all patients 21 to 29 years and those ≥30 years being screened with this method):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cervical cytology is performed every 12 months for a total of three years. Although it is not our practice, some clinicians perform cervical cytology six months after the baseline test since cervical intraepithelial neoplasia (CIN) is not uncommon and can develop rapidly in these patients [
         <a href="#rid2">
          2,11,19
         </a>
         ] and because high-grade lesions may be missed with a single test [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the results of three consecutive cervical cytology tests are normal, follow-up with cervical cytology is performed every three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If screening with
         <strong>
          co-testing
         </strong>
         (those ≥30 years being screened with this method):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeat co-testing is performed every three years; unlike with cervical cytology, consecutive testing every 12 months prior to increasing the interval to three years is not required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do
         <strong>
          not
         </strong>
         perform routine colposcopy at subsequent follow-up visits. This is discussed in more detail below. (See
         <a class="local">
          'Routine colposcopy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform annual follow-up, which includes thorough visual inspection of the anus, vulva, and vagina [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening continues throughout a patient's lifetime (and does not end, as in the general population, at 65 years old).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the incidence of HIV-related infection and cervical cancer appears to peak by age 54 years. In a cohort study including patients with HIV in South Africa, patients ages 30 to 44 years compared with other ages had higher rates of HIV-related infection (54 percent) and cervical cancer (53 percent); the incidence of infection-unrelated cancers surpassed infection-related cancers beginning at age 55 years [
         <a href="#rid21">
          21
         </a>
         ]. Thus, screening for non-HIV-related cancers should not be overlooked.
        </p>
        <p>
        </p>
        <p>
         Patients with advanced HIV disease are more likely to have persistent HPV and CIN than those with early HIV infections. In our practice, we perform more frequent screening if the patient's HIV-related disease is poorly controlled or begins to progress (as measured by rising viral load, falling CD4 level), or if the patient is noncompliant with antiretroviral therapy (ART). However, there are no objective data showing that more aggressive screening is indicated for these patients or that this affects outcome, and there are no national guidelines that promote more frequent screening in this setting.
        </p>
        <p>
         In addition, it has been suggested that the use of ART may reverse or lessen the severity of CIN in patients with HIV as is the case with other AIDS-related malignancies [
         <a href="#rid22">
          22-24
         </a>
         ]. However, multiple studies of this hypothesis have yielded mixed results, and the incidence of invasive cervical cancer appears to be unchanged despite increasing success of HIV viral suppression with ART [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         Patients in whom initial screening is abnormal are managed differently. This is discussed in detail below. (See
         <a class="local">
          'Evaluation of abnormal results'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1734044547">
         <span class="h1">
          RATIONALE AND EVIDENCE FOR SCREENING METHODS
         </span>
        </p>
        <p class="headingAnchor" id="H270054351">
         <span class="h2">
          Cytology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cervical cytology appears to be a reliable primary screening tool for cervical cancer in patients with HIV, though the data regarding the reliability of this technique are conflicting [
         <a href="#rid1">
          1,20,26,28-31
         </a>
         ]. Either conventional Pap smears or liquid-based cervicovaginal preparations may be employed for screening [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">
          "Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"
         </a>
         .)
        </p>
        <p>
         In a multicenter study of 1534 patients with HIV (median age 33 years) in Europe and South Africa, patients were followed with cervical cytology, human papillomavirus (HPV) testing, and colposcopy (with histopathology when indicated) at six-month intervals; median follow-up was approximately two years [
         <a href="#rid34">
          34
         </a>
         ]. Cytology (atypical squamous cells of undetermined significance [ASC-US] or greater) and colposcopy had equivalent sensitivity for detecting patients with cervical intraepithelial neoplasia (CIN) 2 or worse (100 and 98 percent, respectively). HPV testing compared with colposcopy had similar sensitivity (91 percent) but was less specific (50 versus 63 percent). Based on these findings, the authors concluded that cytology was preferable to HPV testing or colposcopy for cervical cancer screening in patients with HIV.
        </p>
        <p>
         In addition, patients with HIV and a history of three negative Pap test results can be screened at three-year intervals. In a prospective study of 942 patients with HIV and three consecutive negative cytology results, after 15 months, there were no cases of precancer (CIN 2,3, atypical glandular cells favor neoplasia, or adenocarcinoma in situ), and after 39 months, precancer was found in 2 percent of participants [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1278910093">
         <span class="h2">
          Cotesting
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of co-testing (ie, HPV testing and cervical cytology) to determine the frequency of subsequent screening in patients with HIV is a reasonable approach in patients ≥30 years.
        </p>
        <p>
         In a cohort study of 855 patients with HIV (mean age 36 years) and CD4 counts over 500 cells/microL, the risk of developing a squamous intraepithelial lesion (SIL) in the subsequent three years after normal cervical cytology and HPV-negative test results was low (6 percent, 95% CI 2-10 percent) and was equivalent to that of patients without HIV [
         <a href="#rid33">
          33
         </a>
         ]. However, patients with CD4 counts less than 200 cells/microL and those between 200 and 500 cells/microL had higher rates of SIL (29 percent, 95% CI 15-44 percent and 14 percent, 95% CI 8-20 percent, respectively).
        </p>
        <p>
         Similarly, in a study of 103 patients with HIV infection and CD4 counts less than 500 cells/microL, the presence of a high-risk HPV subtype, although strongly associated with the presence of any CIN, only slightly improved the sensitivity and predictive value of baseline screening when compared with cytologic screening alone [
         <a href="#rid35">
          35
         </a>
         ]. The lack of substantial benefit was most likely due to the high prevalence of HPV infection in patients with HIV. It appears that patients with HIV are more likely than other patients to be infected with high-risk HPV subtypes other than 16 and 18 and are likely to have persistent infection [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
         Primary HPV testing (ie, HPV testing alone without concurrent cervical cytology), however, is
         <strong>
          not
         </strong>
         a recommended screening method for patients with HIV. Primary HPV tests (ie, cobas and BD Onclarity) have not been adequately studied in patients with HIV, and we, therefore, cannot endorse the use of these tests as a standalone screening technique for this population. In one prospective study including 865 patients with HIV (mean age 46; median CD4 count of 592 cells/microL) undergoing cervical cancer screening, primary HPV testing and primary HPV testing with reflex HPV 16/18 genotyping led to fewer colposcopy referrals (35 and 24 percent, respectively) compared with co-testing (40 percent), but had similar sensitivities [
         <a href="#rid38">
          38
         </a>
         ]. Additional clinical trials are needed to determine if these tests can be used for patients with HIV.
        </p>
        <p class="headingAnchor" id="H4276802869">
         <span class="h2">
          Routine colposcopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, we perform a screening colposcopy along with cervical cytology at the initial examination; however, there are no national guidelines that promote this practice. Colposcopic examination of the vagina and vulva, as well as the cervix, should be included in the evaluation because of the higher risk of multifocal disease [
         <a href="#rid17">
          17,18
         </a>
         ]. We base the need for subsequent colposcopic examinations on cervical cytology results. (See
         <a class="local">
          'Evaluation of abnormal results'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">
          "Colposcopy"
         </a>
         .)
        </p>
        <p>
         Although not our practice, some clinicians perform annual colposcopy in patients with HIV. The rationale for routine colposcopy is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         These patients are usually seen in the health care system more often than once a year for other reasons, so they would not require an additional visit (with its associated costs and inconvenience) just for screening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of cervical dysplasia is high; thus, the potential need for a return visit for colposcopy is eliminated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A higher rate of concurrent vulvar, vaginal, and anal neoplasias occurs in this group [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Even mildly abnormal smears are associated with a high rate of histologic CIN (38 percent in one series) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, one retrospective study of 189 patients with HIV did not find that routine colposcopy improved outcomes [
         <a href="#rid40">
          40
         </a>
         ]. In this study, patients received cervical cancer screening with cytology and colposcopy and were followed for six years; agreement between cytologic findings and colposcopic and histologic findings was high. Of the 19 patients with normal cytology but abnormal biopsy, 95 percent developed abnormal cervical cytology (most commonly ASC-US) within one year; this led the authors to conclude that the routine use of colposcopy in these individuals was not necessary.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          EVALUATION OF ABNORMAL RESULTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American Society for Colposcopy and Cervical Pathology consensus guidelines advise that patients with HIV
         <strong>
          at any age
         </strong>
         with abnormal screening results be managed as follows [
         <a href="#rid12">
          12,13,41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytology-negative, human papillomavirus (HPV)-positive
         </strong>
         – Repeat co-testing in one year (unless genotype testing for 16 or 16/18 is positive).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the initial HPV results identify HPV 16 or HPV 16/18, then colposcopy is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If either of the co-tests at one year is abnormal (ie, abnormal cytology or HPV-positive), colposcopy should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical squamous cells of undetermined significance (ASC-US).
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If reflex HPV testing is positive, colposcopy should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If HPV testing is not available or not done, repeat cytology in 6 to 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For any result equal to or more severe than ASC-US on repeat cytology, colposcopy should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-grade squamous epithelial lesion (LSIL) or more severe lesions
         </strong>
         (including high-grade squamous intraepithelial lesion [HSIL], atypical squamous cells cannot exclude HSIL [ASC-H], or atypical glandular cells [AGC]) – Colposcopy should be performed.
        </p>
        <p>
        </p>
        <p>
         Although rates of cytologic
         <strong>
          glandular
         </strong>
         abnormalities appear to increase with the degree of immunosuppression in patients with HIV, glandular neoplasia is rare. This was illustrated in a large cohort study that included almost 50,000 Pap tests [
         <a href="#rid42">
          42
         </a>
         ]. Rates of glandular abnormalities on cervical cytology did not differ significantly in patients with (0.8 percent) and without (0.6 percent) HIV. Among patients with HIV, on the other hand, the rate of cytologic glandular abnormalities increased significantly with decreasing CD4 lymphocyte count (&gt;500 cells/microL: 0.6 percent; 250 to 500 cells/microL: 0.8 percent; &lt;250 cells/microL: 1.0 percent). Ultimately, cervical biopsy found adenocarcinoma in only one patient with HIV and glandular atypia in one patient without HIV; other patients had negative histology or squamous abnormalities and showed no significant difference by HIV serostatus.
        </p>
        <p class="headingAnchor" id="H678854326">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2721615819">
         <span class="h2">
          Screening after hysterectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our practice, for medically stable patients with HIV who have undergone hysterectomy for benign disease and who have no history of cervical intraepithelial neoplasia (CIN), we do
         <strong>
          not
         </strong>
         perform routine cervical cancer screening. However, if the patient's HIV-related disease begins to progress (as measured by rising viral load, falling CD4 level, opportunistic infection), or viral suppression with antiretroviral therapy (ART) cannot be achieved or maintained, we perform a Pap test or co-testing and pelvic examination, as well as
         <strong>
          annual
         </strong>
         screening from then on.
        </p>
        <p>
         For patients with HIV who have undergone hysterectomy for a reason other than CIN or invasive cancer, there are few data regarding the risk of developing vaginal intraepithelial neoplasia (VaIN) or vaginal cancer [
         <a href="#rid43">
          43,44
         </a>
         ], and no formal guidelines regarding Pap smear screening are available.
        </p>
        <p>
         In a retrospective cohort study of 238 patients with HIV and prior hysterectomy with no history of abnormal Pap smears who underwent follow-up for a median of 16 years, 31 percent (74 patients) were found to have abnormal cytology [
         <a href="#rid43">
          43
         </a>
         ]. Of these patients, 54 had vaginal biopsies with the following distribution of results: normal (28 percent), VaIN 1 (43 percent), VaIN 2 (16 percent), and VaIN 3 (13 percent); no patients had invasive vaginal cancer. Patients who did not require ART at any point after hysterectomy were more likely to have normal compared with abnormal cytology results (91 versus 9 percent).
        </p>
        <p class="headingAnchor" id="H2187701812">
         <span class="h2">
          Immunosuppressed patients without HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients without HIV who are on long-term immunosuppressive therapy also have decreased rates of clearance of human papillomavirus (HPV) infection and increased rates of cervical dysplasia and cancer [
         <a href="#rid14">
          14,45-50
         </a>
         ]. These include patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solid organ transplant [
         <a href="#rid14">
          14,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">
          "Malignancy after solid organ transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allogeneic hematopoietic stem cell transplant [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus [
         <a href="#rid14">
          14,45,47-50,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory bowel disease requiring
         <strong>
          current
         </strong>
         immunosuppressive treatments [
         <a href="#rid14">
          14,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">
          "Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Cancer screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatologic disease (eg, rheumatoid arthritis) requiring
         <strong>
          current immunos
         </strong>
         uppressive treatments [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presumed hypothalamic-pituitary-adrenal axis (HPA) suppression from long-term or high-dose glucocorticoid use. (See
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal", section on 'Identifying patients with HPA suppression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For these patients, we follow the same cervical cancer screening guidelines as for patients with HIV, as discussed in detail above  (
         <a class="graphic graphic_table graphicRef129717" href="/z/d/graphic/129717.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         As with patients with HIV, patients on long-term immunosuppressive therapy and normal screening results are candidates for subsequent screening every three years. In one retrospective study including 310 patients (ages 18 to 60 years) with benign cervical cancer screening after solid organ transplant, 284 patients (92 percent) continued to have normal screening results through 60 months [
         <a href="#rid54">
          54
         </a>
         ]. Of the 26 patients with abnormal cervical cytology, 17 had low-grade lesions, five had high-grade lesions, and four had atypical glandular or endometrial cells; no patients developed cervical cancer during the study period.
        </p>
        <p class="headingAnchor" id="H1532696068">
         <span class="h2">
          Patients not actively on immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with inflammatory bowel disease or rheumatoid arthritis
         <strong>
          not
         </strong>
         actively on immunosuppressive therapy, as well as those with type 1 diabetes mellitus, are
         <strong>
          not
         </strong>
         at higher risk for cervical cancer and should follow cervical cancer screening guidelines for average-risk patients  (
         <a class="graphic graphic_table graphicRef129717" href="/z/d/graphic/129717.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Screening in average-risk patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3240048604">
         <span class="h2">
          Patients with barriers to screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Barriers to cervical cancer screening include lack of access to gynecologic care and fear of a pelvic examination. Some HIV clinics offer cervical cancer screening, allowing patients with HIV to omit a separate visit for a pelvic examination. Although one study in HIV-positive patients suggested that self-collected primary HPV testing may be an effective screening strategy, primary HPV is not approved for screening in patients with HIV [
         <a href="#rid55">
          55
         </a>
         ]. Further study is needed to determine if primary HPV testing, as well as self-collection of HPV samples, is an option for patients with HIV. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Relative risks and benefits of each method'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Types of screening and frequency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3202.html" rel="external">
          "Screening for cervical cancer in resource-limited settings", section on 'Self-collected samples'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2265097896">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111628.html" rel="external">
          "Society guideline links: Primary care of adults with HIV"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117738.html" rel="external">
          "Society guideline links: Cervical cancer screening, prevention, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial screening
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with HIV, cervical cancer screening starts at the time of HIV diagnosis, but no sooner than age 21 years; the risk of developing cervical cancer prior to the age of 25 years is rare. (See
         <a class="local">
          'Initial screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For all patients with HIV presenting for their initial cervical cancer screening visit, we suggest the addition of screening colposcopy to cervical cytology or co-testing (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The need for subsequent colposcopies is based on cervical cytology results. (See
         <a class="local">
          'Initial screening'
         </a>
         above and
         <a class="local">
          'Routine colposcopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type of screening and screening intervals
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients 21 to 29 years, we suggest cervical cytology for screening rather than co-testing (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients ≥30 years, either cervical cytology or co-testing (cervical cytology and human papillomavirus [HPV] testing) is acceptable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If using cytology alone, annual cervical cytology is performed every three years; if results of the three consecutive cytology results are normal, cytology is then performed every three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If using co-testing and the results of both cytology and HPV are negative, co-testing is performed every three years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We also perform an annual examination that includes thorough visual inspection of the anus, vulva, and vagina. (See
         <a class="local">
          'Initial screening'
         </a>
         above and
         <a class="local">
          'Subsequent screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifelong screening
         </strong>
         – Cervical cancer screening in patients with HIV should continue throughout a patient's lifetime (and not end, as in the general population, at 65 years old). (See
         <a class="local">
          'Subsequent screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of abnormal screening results
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeat cytology is performed in one year for the following – Cytology-negative, HPV-positive (but negative for 16/18); atypical squamous cells of undetermined significance (ASC-US), HPV-unknown. (See
         <a class="local">
          'Evaluation of abnormal results'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Colposcopy is performed for any of the following results – HPV 16/18; ASC-US, HPV-positive; low-grade squamous epithelial lesion (LSIL) or worse. (See
         <a class="local">
          'Evaluation of abnormal results'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressed patients without HIV
         </strong>
         – Patients without HIV who are on long-term immunosuppressive therapy (eg, solid organ transplant, allogeneic hematopoietic stem cell transplant, systemic lupus erythematous, and those with inflammatory bowel disease or rheumatologic disease requiring
         <strong>
          current
         </strong>
         immunosuppressive treatments) have decreased rates of clearance of HPV infection and increased rates of cervical dysplasia and cancer. For these patients, we follow the same cervical cancer screening guidelines as for patients with HIV infection  (
         <a class="graphic graphic_table graphicRef129717" href="/z/d/graphic/129717.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Immunosuppressed patients without HIV'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifford GM, Gonçalves MA, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oster AM, Sullivan PS, Blair JM. Prevalence of cervical cancer screening of HIV-infected women in the United States. J Acquir Immune Defic Syndr 2009; 51:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. Obstet Gynecol 2016; 128:e111. Reaffirmed 2020.
          </a>
         </li>
         <li class="breakAll">
          https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on August 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins–Gynecology. Practice Bulletin No. 167: Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus. Obstet Gynecol 2016; 128:e89. Reaffirmed 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. J Low Genit Tract Dis 2019; 23:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson MA, Horberg MA, Agwu AL, et al. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2021; 73:e3572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stier EA, Engels E, Horner MJ, et al. Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002-2016. AIDS 2021; 35:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palefsky JM. Human papillomavirus-associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals. Curr Opin Oncol 1991; 3:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abercrombie PD, Korn AP. Lower genital tract neoplasia in women with HIV infection. Oncology (Williston Park) 1998; 12:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb K, Maiman M, Dimaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 1998; 91:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruffieux Y, Muchengeti M, Olago V, et al. Age and Cancer Incidence in 5.2 Million People With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study. Clin Infect Dis 2023; 76:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soncini E, Zoncada A, Condemi V, et al. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massad LS, DʼSouza G, Tian F, et al. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. Obstet Gynecol 2012; 120:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olaitan A, Mocroft A, McCarthy K, et al. Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstet Gynecol 1997; 89:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998; 68:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swierczynski SL, Lewis-Chambers S, Anderson JR, et al. Impact of liquid-based gynecologic cytology on an HIV-positive population. Acta Cytol 2004; 48:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitchener H, Nelson L, Adams J, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121:2484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn JA, Gagnon S, Spence MR, et al. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based Clinical Trials Network. Am J Obstet Gynecol 2001; 184:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenzie ND, Kobetz EN, Hnatyszyn J, et al. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol 2010; 116:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heard I, Cubie HA, Mesher D, et al. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2013; 120:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickler HD, Keller MJ, Hessol NA, et al. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. Clin Infect Dis 2021; 72:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562.
          </a>
         </li>
         <li class="breakAll">
          www.ASCCP.org (Accessed on October 08, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massad LS, Xie X, Darragh TM, et al. Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet Gynecol 2009; 114:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeltzer S, Yu X, Schmeler K, Levison J. Abnormal Vaginal Pap Test Results After Hysterectomy in Human Immunodeficiency Virus-Infected Women. Obstet Gynecol 2016; 128:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paramsothy P, Duerr A, Heilig CM, et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 2004; 35:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klumb EM, Araújo ML Jr, Jesus GR, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol 2010; 16:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen ML, Flowers L. Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin North Am 2013; 40:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007; 57:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010; 9:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tam LS, Chan PK, Ho SC, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011; 63:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruera S, Lei X, Zogala R, et al. Cervical Cancer Screening in Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2021; 73:1796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009; 136:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long ME, Chantigian PDM, Weaver AL. Would Women With Solid Organ Transplant Qualify for Triennial Cervical Cancer Screening as Recommended by the American College of Obstetricians and Gynecologists in 2016 and American Society for Colposcopy and Cervical Pathology in 2019? J Low Genit Tract Dis 2021; 25:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang R, Lee K, Gaydos CA, et al. Performance of Primary Self-Collected Human Papillomavirus Testing Among Women Living With Human Immunodeficiency Virus in the United States. Obstet Gynecol 2021; 137:342.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3220 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8090399" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10697063" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Incidence of cervical squamous intraepithelial lesions in HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15378433" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840880" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117020" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Human papillomavirus types among women infected with HIV: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10995805" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12838307" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of cancer in persons with AIDS in Italy, 1985-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16106415" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19474756" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevalence of cervical cancer screening of HIV-infected women in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27661651" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Practice Bulletin No. 168: Cervical Cancer Screening and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27661651" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Practice Bulletin No. 168: Cervical Cancer Screening and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27661659" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Practice Bulletin No. 167: Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32243307" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30907775" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33225349" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34049357" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1661170" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Human papillomavirus-associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9874847" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lower genital tract neoplasia in women with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9572187" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12712082" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36461916" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Age and Cancer Incidence in 5.2 Million People With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11874637" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11262450" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17687815" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15040532" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15265968" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17565153" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : AIDS-related cancer and severity of immunosuppression in persons with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996096" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9190970" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8990441" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9570972" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15085748" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Impact of liquid-based gynecologic cytology on an HIV-positive population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15784870" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17683070" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228481" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based Clinical Trials Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906410" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121095" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Characteristics of HPV infection over time in European women who are HIV-1 positive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32881999" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8602301" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Significance of mild cytologic atypia in women infected with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421802" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Accuracy of Papanicolaou test among HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16421802" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Accuracy of Papanicolaou test among HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20168108" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27275815" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Abnormal Vaginal Pap Test Results After Hysterectomy in Human Immunodeficiency Virus-Infected Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15021313" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20407390" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23732035" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cervical cancer screening in immunocompromised women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17471531" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19643208" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Malignancies in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20890985" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20605875" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Are women with lupus at higher risk of HPV infection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15153569" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Malignancy in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32799430" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cervical Cancer Screening in Women With Systemic Lupus Erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18996382" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33631778" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Would Women With Solid Organ Transplant Qualify for Triennial Cervical Cancer Screening as Recommended by the American College of Obstetricians and Gynecologists in 2016 and American Society for Colposcopy and Cervical Pathology in 2019?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33416287" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Performance of Primary Self-Collected Human Papillomavirus Testing Among Women Living With Human Immunodeficiency Virus in the United States.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
